The CDC42 effector protein MRCKß autophosphorylates on Threonine 1108. (2020)
Attributed to:
Development of a novel drug targeting MRCK and ROCKII for the treatment of invasive and/or metastatic cancer.
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1080/21541248.2018.1564472
PubMed Identifier: 30667325
Publication URI: http://europepmc.org/abstract/MED/30667325
Type: Journal Article/Review
Volume: 11
Parent Publication: Small GTPases
Issue: 6
ISSN: 2154-1248